Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

When HIV infects a CD4 cell in a person's body, it copies its own genetic code into the cell's DNA. In this way, the cell is then "programmed" to create new copies of HIV. HIV's genetic material is in the form of RNA. In order for it to infect CD4 cells, it must first convert its RNA into DNA. HIV's reverse transcriptase enzyme is needed to perform this process.

NNRTIs, also known as "non-nucleosides" or "non-nukes" for short, attach themselves to reverse transcriptase and prevent the enzyme from converting RNA to DNA. In turn, HIV's genetic material cannot be incorporated into the healthy genetic material of the cell, and prevents the cell from producing new virus.

*generic or biosimilar available

E experimental

DRUG Edurant
GENERIC NAME rilpivirine
COMPANY Janssen Therapeutics
DRUG Intelence
GENERIC NAME etravirine
COMPANY Janssen Therapeutics
DRUG Pifeltro
GENERIC NAME doravirine
COMPANY Merck & Company
DRUG Rescriptor
GENERIC NAME delavirdine
COMPANY ViiV Healthcare
DRUG Sustiva*
GENERIC NAME efavirenz
COMPANY Bristol-Myers Squibb
DRUG Viramune and Viramune XR*
GENERIC NAME nevirapine
COMPANY Boehringer-Ingelheim

Last Reviewed: March 14, 2019


Hot topics